FDAnews
www.fdanews.com/articles/102671-elan-transition-begin-alzheimer-s-trial

Elan, Transition Begin Alzheimer's Trial

December 31, 2007

Ireland’s Elan and Canadian drugmaker Transition Therapeutics have dosed the first patient in a Phase II study of ELND005 in patients with Alzheimer's disease.

The randomized, double-blind, placebo-controlled, dose-ranging study enrolled approximately 340 patients with mild to moderate Alzheimer's disease.

The study will evaluate cognitive and functional endpoints, and patients will participate in the trial for approximately 18 months, according to Elan.